Articles

Cardiovascular outcomes often dominate discussions about GLP-1 receptor agonists, but what about nerve health? Growing interest in GLP-1 diabetic neuropathy reflects a broader shift toward understanding microvascular complications beyond heart disease. While medications such as semaglutide (Ozempic), dulaglutide (Trulicity), and liraglutide (Victoza) have proven cardiovascular benefits, their potential influence on …

As GLP-1 receptor agonists dominate headlines and prescribing trends, many clinicians wonder whether older therapies are losing relevance. However, SGLT2 inhibitors remain foundational in type 2 diabetes care. More importantly, evidence now supports the use of SGLT2 inhibitors and GLP-1 combination therapy in patients at high cardiovascular and renal risk. …

In 2026, diabetic retinopathy screening is entering a new era driven by artificial intelligence, tele-retinal imaging, and smarter integration into primary care workflows. Despite improved glucose monitoring and widespread use of CGM systems, diabetic retinopathy remains a leading cause of preventable blindness in adults with diabetes. So how can clinicians …

The arrival of a once-weekly basal insulin option marks one of the most meaningful advances in insulin therapy in decades. For years, daily basal injections have been the standard of care for people with type 1 and type 2 diabetes. However, many patients struggle with adherence, missed doses, and therapeutic …

Inflammation sits at the heart of cardiometabolic disease. While GLP-1 receptor agonists are best known for improving glycemic control and supporting weight loss, emerging research suggests their role may extend further. Could the anti-inflammatory effects of GLP-1 therapies help explain some of the cardiovascular benefits observed in large outcome trials? …

Changes in resting heart rate with GLP-1 receptor agonists have become an important topic in diabetes and cardiometabolic care. As glucagon-like peptide-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide gain widespread use, clinicians often notice a modest rise in resting heart rate. Should this increase raise concern, especially in …

The link between metabolism and reproduction is gaining attention, especially as questions about GLP-1 therapy and male fertility begin to surface in clinical practice. For years, male fertility evaluations focused mainly on hormones and anatomy. However, what if the root problem starts with metabolic health? Obesity and insulin resistance are …

Patients using GLP-1 receptor agonists are reporting something unexpected: less joint and musculoskeletal pain. As interest grows in how GLP-1 therapies may affect chronic pain, clinicians are asking an important question. Are these improvements simply the result of weight loss, or do GLP-1 medications have direct anti-inflammatory and neuromodulatory effects? …

The conversation around GLP-1 therapies has shifted quickly. While most clinicians focus on weight loss and glucose lowering, new data on GLP-1 microbiome effects suggest something deeper may be happening in the gut. Could these medications reshape the intestinal ecosystem in ways that support long-term metabolic health? Increasingly, researchers believe …

Concerns about GLP-1 pancreatic cancer risk have circulated for more than a decade. When glucagon-like peptide-1 receptor agonists first entered the market, early post-marketing reports and small observational studies raised alarms about pancreatitis and possible malignancy. As a result, clinicians and patients questioned the long-term safety of agents such as …